KSKazuhiro Seike

Kazuhiro Seike

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kazuhiro Seike has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Voice Trial-Results from a Multicenter Phase Ii Study of Assessment of Clinical Efficacy and Safety in Capecitabine Plus Intermittent Oxaliplatin Together with Bevacizumab As the First-Line Therapy for the Patients with Advanced Colorectal Cancer

    by C. Kosugi, K. Koda, T. Denda, K. Ishibashi, H. Ishida, K. Seike, H. Sakata, S. Yanagisawa, T. Natsume, W. Takayama, et al.

    Aim: The FOLFOX with bevacizumab regimen has been established as a standard first-line therapy for metastatic colorectal cancer (mCRC), and the OPTIMOX1 study suggested that a stop and go strategy for oxaliplatin reduced peripheral sensory neuropathy. We had already evaluated the efficacy of OPTIMOX1 plus bevacizumab in patients (pts) with mCRC (CRAFT study, Tezuka et al, Invest New Drugs 2013). CapeOx is one of the standard treatments for mCRC that has been proven to be as effective as the FOLFOX regimen. Thus we assessed the efficacy and safety of the combination of intermittent CapeOx + Bevacizumab as a first-line therapy in patients with mCRC in this trial. Methods: Eligibility criteria included ECOG PS: 0–1, no peripheral neuropathy (2, capecitabine 2000mg/m2 + bevacizumab 7.5mg/kg) q3 weeks for 5 cycles, maintenance without oxaliplatin for 5 cycles, and reintroduction CapeOX + bevacizumab for 5 cycles until progression. Primary endpoint was progression-free survival (PFS). Results: Between March 2011 and August 2013, 55 pts were enrolled. Baseline characteristics were median age of 67 years (range, 20–83); PS 0/1 (49/6 pts); male/female(33/22 pts), colon/rectum (28/27pts) and metastatic lesion liver/lung/lymph nodes (32/18/21 pts). A total of 47 pts were evaluated as Par Protocol Set population. 38 pts moved from initial CapeOX to maintenance capecitabine. 20 pts moved to CapeOx reintroduction. Median PFS was 12.4 months (95%CI, 7.7–17.1) and Median TTF was 8.3 months (95%CI, 4.5–12.1). Best overall response rate was 50.9%. Median capecitabine courses were 5 cycles (range 1–5). Oxaliplatin reintroduction rate was 52%. The causes of reintroduction failure were disease progression (3 pts), successful liver resection (2 pts), peripheral sensory neuropathy grade 2 (1 pt). Main grade 3/4 toxicities: neutropenia, anemia, peripheral neuropathy, hand-foot syndrome, and hypertension in 1 patient. Conclusions: This study met its primary endpoint PFS. It was longer than the CRAFT study. CapeOx with intermittent oxaliplatin is indicated to reduce incidence of severe neutropenia and peripheral sensory neuropathy. The results suggested that our treatment strategy was well tolerated and effective for first-line therapy in mCRC, and maintenance of duration for 5 cycles was reasonable. Disclosure: All authors have declared no conflicts of interest.

  • Open Access

    Advanced moderately differentiated neuroendocrine carcinoma of the rectum with favorable prognosis by postoperative chemoradiation

    by Hiroyuki Nojima, Kazuhiro Seike, Chihiro Kosugi, Takashi Shida, Keiji Koda, Kenji Oda, Shigeyuki Kamata, Hiroshi Ishikura, Masaru Miyazaki

    Rectal neuroendocrine carcinoma is rare with poor prognosis. We report herein a case of advanced moderately differentiated neuroendocrine carcinoma of the rectum with relatively favorable prognosis treated by postoperative adjuvant chemoradiation therapy. A 58-year-old Japanese female was referred and colonofiberscopy revealed an easy-bleeding irregular tumor in the lower rectum, which was pathologically diagnosed as a neuroendocrine carcinoma. Surgical treatment consisted of abdominoperineal resection and lymph node dissection. The tumor invaded deeply into perirectal tissues, and 9 of 11 lymph node metastases were observed. Immunohistochemically, chromogranin A showed diffuse and strong staining, and the MIB-1 labeling index was 18.3 ± 5.6, supporting the high proliferation of the tumor. Some nucleus of the tumor showed positive staining for p21/WAF1. A total dose of 46 Gy of radiotherapy was delivered with 800 mg of daily oral doxifluridine. At 5 years post-surgery, the patient demonstrated no clinical evidence of intrapelvic recurrence or distant metastases.


    • 21 May 2009
      • Vol. 56  (89) , 111-5

    Gender differences in pelvic anatomy and effects on rectal cancer surgery.

    by Kazuhiro Seike, Keiji Koda, Kenji Oda, Chihiro Kosugi, Kimio Shimizu, Masaru Miyazaki

    The male pelvis is said to be narrower and deeper than the female pelvis. The present study aimed to evaluate anatomical differences in the pelvis between genders, and to analyze effects on rectal cancer surgery. Gender differences in pelvic anatomy were evaluated using computed tomography in 78 Japanese patients who had received low anterior resection for rectal cancer. Factors affecting operative duration and intraoperative blood loss were analyzed for both low anterior resection and ultra-low anterior resection. Pelvic capacity was significantly lower in males (460.0 +/- 16.7 cm3) than in females (634.8 +/- 22.0 cm3; p < 0.0001), and level of the levator ani compared to the upper edge of the pubis was significantly lower in males than in females. Surgical parameters in ultra-low anterior resection were affected by level of the levator ani, tumor volume and tumor height compared to the upper edge of the pubis, not by tumor height above anal verge. The pelvis was narrower and deeper in males than in females. Obtaining good visualization is critical particularly in performing ultra-low anterior resection against a large tumor located below the upper edge of the pubis in a patient who has deep pelvic floor.


  • Laser Doppler assessment of the influence of division at the root of the inferior mesenteric artery on anastomotic blood flow in rectosigmoid cancer surgery

    by Kazuhiro Seike, Keiji Koda, Norio Saito, Kenji Oda, Chihiro Kosugi, Kimio Shimizu, Masaru Miyazaki

    The aim of this study is to evaluate the influence of dividing the inferior mesenteric artery (IMA) and preserving the left colic artery (LCA) on rectosigmoid cancer surgery.


  • Relevance of Abdominal Gas Analysis and Transit Study after Colorectal Cancer Surgery

    by K. Seike, K. Koda, K. Oda, E. Kondo, M. Ishizuka, M. Miyazaki

    Background: Colon gas volume analysis using abdominal radiographs is an objective and reproducible method for evaluating functional bowel disorders. The aim of this study was to clarify the relevance of colon gas distribution and transit time in rectosigmoid cancer patients after surgery. Methods: Segmental colon gas volume score was calculated using plain abdominal radiography and evaluated in 40 patients who had undergone sphincter-saving resection. Segmental colonic transit time was analysed using radiopaque markers in the same patients. Results: Transit times in the right colon (RCT) were 15.3 ± 1.1 h and in the left colon (LCT) 11.2 ± 1.1 h. Gas volume scores in the RCS and LCS were 1.10 ± 0.13% and 1.06 ± 0.14%, respectively. Neither colonic transit time nor colon gas volume score correlated with the operation methods for rectosigmoid colon cancer. A positive correlation of RCS and a negative correlation of LCS/RCS with ageing were noted in male patients but not in female patients. There was no correlation between RCT and RCS (r = 0.028); however, LCT correlated with LCS (r = 0.318, P < 0.05). The ratio of colonic transit time (LCT/RCT) was 0.84 ± 0.10, while that of colon gas volume score (LCS/RCS) was 1.29 ± 0.21. There was a significant correlation between LCT/RCT and LCS/RCS (r = 0.541, P < 0.001). Conclusions: Analysis of colon gas volume is useful for evaluating colonic transit time in rectosigmoid cancer patients after sphincter-saving surgery.